Skip to main content
Clinical Trials/NL-OMON30305
NL-OMON30305
Not yet recruiting
Phase 4

PITUITARY DAMAGE AFTER TRAUMATIC BRAIN INJURY; Occurrence of growth hormone deficiency at long term follow-up and the beneficial effects of growth hormone substitution on cardiovascular performance, quality of life and functional abilities - Growth hormone substitution in isolated growth hormone deficiency after TBI

niversitair Medisch Centrum Sint Radboud0 sites50 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
traumatologische aandoeningen
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
50
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • 1\. The patient visits the emergency department with mild, moderate or severe traumatic brain injury. (Mild traumatic brain injury is defined as a history of impact to the head and a Glasgow Coma Scale score (GCS) 13\-15 at entry in the emergency room, moderate traumatic brain injury is defined as a GCS 9\-12 at entry in the emergency room, and severe traumatic brain injury is defined as a GCS \<\= 8 at entry in the emergency room)
  • 2\. The trauma has occurred less than 24 hours before visiting the emergency department.
  • 3\. Age \>\= 18 years and \<\= 65 years at the time of inclusion
  • 4\. Absolute growth hormone deficiency (defined as growth hormone response \< 9 mE/l in the GHRH\-arginine test), diagnosed within one of the protocols going with ABR form no. 14996 or 14998

Exclusion Criteria

  • 1\. Age \> 65 or \< 18 years
  • 2\. No oral or written informed consent by patient
  • 3\. Pre\-existent neuro\-endocrine disorder
  • 4\. Co\-existent dysfunction of pituitary axis other than the somatotropic axis
  • 5\. Instable infiltrative disease in the hypothalamus/pituitary region (eg sarcoidosis, tumour metastasis)
  • 6\. BMI \>30 kg/m2
  • 7\. Primary dyslipidemia that necessitates treatment
  • 8\. Positive family history of premature cardiovascular disease
  • 9\. Overt diabetes mellitus type II (including a history of gestational diabetes mellitus)
  • 10\. Impairment in renal function (Creatinin clearance \< 60 ml/min)

Outcomes

Primary Outcomes

Not specified

Similar Trials